ID   HIF3A_HUMAN             Reviewed;         669 AA.
AC   Q9Y2N7; B0M185; B4DNA2; I6L988; Q58A43; Q66K72; Q8WXA1; Q96K34; Q9H7Z9;
AC   Q9HAI2;
DT   17-APR-2007, integrated into UniProtKB/Swiss-Prot.
DT   17-APR-2007, sequence version 2.
DT   28-JUN-2023, entry version 174.
DE   RecName: Full=Hypoxia-inducible factor 3-alpha {ECO:0000303|PubMed:11573933};
DE            Short=HIF-3-alpha {ECO:0000303|PubMed:11573933};
DE            Short=HIF3-alpha;
DE   AltName: Full=Basic-helix-loop-helix-PAS protein MOP7;
DE   AltName: Full=Class E basic helix-loop-helix protein 17;
DE            Short=bHLHe17;
DE   AltName: Full=HIF3-alpha-1;
DE   AltName: Full=Inhibitory PAS domain protein;
DE            Short=IPAS;
DE   AltName: Full=Member of PAS protein 7;
DE   AltName: Full=PAS domain-containing protein 7;
GN   Name=HIF3A {ECO:0000312|HGNC:HGNC:15825};
GN   Synonyms=BHLHE17, MOP7, PASD7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=11573933; DOI=10.1006/bbrc.2001.5659;
RA   Hara S., Hamada J., Kobayashi C., Kondo Y., Imura N.;
RT   "Expression and characterization of hypoxia-inducible factor (HIF)-3alpha
RT   in human kidney: suppression of HIF-mediated gene expression by HIF-
RT   3alpha.";
RL   Biochem. Biophys. Res. Commun. 287:808-813(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Cheng J.Q.;
RT   "Cloning and characterization of human inhibitory PAS domain protein.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION (ISOFORM 4), INTERACTION
RP   WITH HIF1A AND ARNT (ISOFORM 4), INDUCTION (ISOFORM 4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Cerebellum;
RX   PubMed=16126907; DOI=10.1096/fj.05-3788com;
RA   Maynard M.A., Evans A.J., Hosomi T., Hara S., Jewett M.A., Ohh M.;
RT   "Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-
RT   regulated in renal cell carcinoma.";
RL   FASEB J. 19:1396-1406(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Kidney;
RA   Hara S., Hosomi T., Mita M., Sakaue M., Kondo Y.;
RT   "HIF-3alpha2, one of splicing variants of human hypoxia-inducible factor-
RT   3alpha, functions as an inhibitor of hypoxia-induced gene expression and
RT   tumor growth.";
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 7), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-626 (ISOFORM 5), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1-233 (ISOFORM 6), AND VARIANT ARG-343.
RC   TISSUE=Embryo, Heart, and Ovary;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4), AND VARIANT
RP   ARG-343.
RC   TISSUE=Brain, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH VHL (ISOFORM 2), ALTERNATIVE SPLICING, UBIQUITINATION AT
RP   LYS-467 AND LYS-570, HYDROXYLATION AT PRO-492, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF LYS-467; PRO-492 AND LYS-570.
RX   PubMed=12538644; DOI=10.1074/jbc.m208681200;
RA   Maynard M.A., Qi H., Chung J., Lee E.H., Kondo Y., Hara S., Conaway R.C.,
RA   Conaway J.W., Ohh M.;
RT   "Multiple splice variants of the human HIF-3 alpha locus are targets of the
RT   von Hippel-Lindau E3 ubiquitin ligase complex.";
RL   J. Biol. Chem. 278:11032-11040(2003).
RN   [10]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=16775626; DOI=10.1038/sj.cr.7310072;
RA   Li Q.F., Wang X.R., Yang Y.W., Lin H.;
RT   "Hypoxia upregulates hypoxia inducible factor (HIF)-3alpha expression in
RT   lung epithelial cells: characterization and comparison with HIF-1alpha.";
RL   Cell Res. 16:548-558(2006).
RN   [11]
RP   FUNCTION (ISOFORM 4), AND INTERACTION WITH EPAS1 (ISOFORM 4).
RX   PubMed=17998805; DOI=10.4161/cc.6.22.4947;
RA   Maynard M.A., Evans A.J., Shi W., Kim W.Y., Liu F.F., Ohh M.;
RT   "Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma
RT   progression.";
RL   Cell Cycle 6:2810-2816(2007).
RN   [12]
RP   FUNCTION (ISOFORMS 3 AND 4), SUBCELLULAR LOCATION, INDUCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=19694616; DOI=10.1042/bj20090120;
RA   Tanaka T., Wiesener M., Bernhardt W., Eckardt K.U., Warnecke C.;
RT   "The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target
RT   gene and may modulate hypoxic gene induction.";
RL   Biochem. J. 424:143-151(2009).
RN   [13]
RP   FUNCTION (ISOFORMS 3 AND 4), ALTERNATIVE SPLICING, TISSUE SPECIFICITY
RP   (ISOFORMS 2; 3 AND 4), AND INDUCTION.
RX   PubMed=20416395; DOI=10.1016/j.biocel.2010.04.008;
RA   Pasanen A., Heikkila M., Rautavuoma K., Hirsila M., Kivirikko K.I.,
RA   Myllyharju J.;
RT   "Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative
RT   splicing in human tissues and cancer cells and is regulated by HIF-1 but
RT   not HIF-2.";
RL   Int. J. Biochem. Cell Biol. 42:1189-1200(2010).
RN   [14]
RP   FUNCTION (ISOFORMS 3 AND 5), TISSUE SPECIFICITY, AND INDUCTION (ISOFORMS 2;
RP   3 AND 5).
RX   PubMed=21069422; DOI=10.1007/s00018-010-0575-4;
RA   Augstein A., Poitz D.M., Braun-Dullaeus R.C., Strasser R.H., Schmeisser A.;
RT   "Cell-specific and hypoxia-dependent regulation of human HIF-3alpha:
RT   inhibition of the expression of HIF target genes in vascular cells.";
RL   Cell. Mol. Life Sci. 68:2627-2642(2011).
CC   -!- FUNCTION: Acts as a transcriptional regulator in adaptive response to
CC       low oxygen tension. Acts as a regulator of hypoxia-inducible gene
CC       expression (PubMed:11573933, PubMed:16126907, PubMed:19694616,
CC       PubMed:20416395, PubMed:21069422). Functions as an inhibitor of
CC       angiogenesis in hypoxic cells of the cornea. Plays a role in the
CC       development of the cardiorespiratory system. May also be involved in
CC       apoptosis (By similarity). {ECO:0000250|UniProtKB:Q0VBL6,
CC       ECO:0000269|PubMed:11573933, ECO:0000269|PubMed:16126907,
CC       ECO:0000269|PubMed:19694616, ECO:0000269|PubMed:20416395,
CC       ECO:0000269|PubMed:21069422}.
CC   -!- FUNCTION: [Isoform 2]: Attenuates the ability of transcription factor
CC       HIF1A to bind to hypoxia-responsive elements (HRE) located within the
CC       enhancer/promoter of hypoxia-inducible target genes and hence inhibits
CC       HRE-driven transcriptional activation. Also inhibits hypoxia-inducible
CC       ARNT-mediated gene expression. {ECO:0000269|PubMed:11573933}.
CC   -!- FUNCTION: [Isoform 3]: Attenuates the ability of transcription factor
CC       HIF1A to bind to hypoxia-responsive elements (HRE) located within the
CC       enhancer/promoter of hypoxia-inducible target genes and hence inhibits
CC       HRE-driven transcriptional activation. {ECO:0000269|PubMed:19694616,
CC       ECO:0000269|PubMed:20416395, ECO:0000269|PubMed:21069422}.
CC   -!- FUNCTION: [Isoform 4]: Attenuates the ability of transcription factor
CC       HIF1A and EPAS1/HIF2A to bind to hypoxia-responsive elements (HRE)
CC       located within the enhancer/promoter of hypoxia-inducible target genes
CC       and hence inhibits HRE-driven transcriptional activation
CC       (PubMed:16126907, PubMed:17998805, PubMed:19694616, PubMed:20416395).
CC       May act as a tumor suppressor and inhibits malignant cell
CC       transformation (PubMed:17998805). {ECO:0000269|PubMed:16126907,
CC       ECO:0000269|PubMed:17998805, ECO:0000269|PubMed:19694616,
CC       ECO:0000269|PubMed:20416395}.
CC   -!- FUNCTION: [Isoform 5]: Attenuates the ability of transcription factor
CC       HIF1A to bind to hypoxia-responsive elements (HRE) located within the
CC       enhancer/promoter of hypoxia-inducible target genes and hence inhibits
CC       HRE-driven transcriptional activation. {ECO:0000269|PubMed:21069422}.
CC   -!- SUBUNIT: Isoform 2 interacts (via ODD domain) with VHL (via beta
CC       domain) (PubMed:12538644). Isoform 4 interacts with HIF1A; the
CC       interaction inhibits the binding of HIF1A to hypoxia-responsive element
CC       (HRE) and HIF1A/ARNT-dependent transcriptional activation
CC       (PubMed:16126907). Isoform 4 interacts with ARNT; the interaction
CC       occurs in a HIF1A- and DNA-binding-independent manner and does not
CC       induce HIF1A/ARNT-dependent transcriptional activation
CC       (PubMed:16126907). Isoform 4 interacts with EPAS1 (PubMed:17998805).
CC       Interacts with BAD, BCL2L2 and MCL1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q0VBL6, ECO:0000269|PubMed:12538644,
CC       ECO:0000269|PubMed:16126907, ECO:0000269|PubMed:17998805}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16775626,
CC       ECO:0000269|PubMed:19694616}. Cytoplasm {ECO:0000269|PubMed:19694616}.
CC       Nucleus speckle {ECO:0000250|UniProtKB:Q0VBL6}. Mitochondrion
CC       {ECO:0000250|UniProtKB:Q0VBL6}. Note=In the nuclei of all periportal
CC       and perivenous hepatocytes. In the distal perivenous zone, detected in
CC       the cytoplasm of the hepatocytes. Shuttles between the nucleus and the
CC       cytoplasm in a CRM1-dependent manner. Colocalizes with BAD in the
CC       cytoplasm. Colocalizes with EPAS1 and HIF1A in the nucleus and speckles
CC       (By similarity). Localized in the cytoplasm and nuclei under normoxia,
CC       but increased in the nucleus under hypoxic conditions
CC       (PubMed:19694616). Colocalized with HIF1A in kidney tumors
CC       (PubMed:19694616). {ECO:0000250|UniProtKB:Q0VBL6,
CC       ECO:0000250|UniProtKB:Q9JHS2, ECO:0000269|PubMed:19694616}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.
CC         {ECO:0000303|PubMed:12538644, ECO:0000303|PubMed:20416395};
CC       Name=1;
CC         IsoId=Q9Y2N7-1; Sequence=Displayed;
CC       Name=2; Synonyms=HIF-3alpha1 {ECO:0000303|PubMed:12538644};
CC         IsoId=Q9Y2N7-2; Sequence=VSP_024520;
CC       Name=3; Synonyms=HIF-3alpha2 {ECO:0000303|PubMed:12538644};
CC         IsoId=Q9Y2N7-3; Sequence=VSP_024526;
CC       Name=4; Synonyms=HIF-3alpha4 {ECO:0000303|PubMed:12538644};
CC         IsoId=Q9Y2N7-4; Sequence=VSP_024523, VSP_024525;
CC       Name=5; Synonyms=HIF-3alpha3 {ECO:0000303|PubMed:12538644};
CC         IsoId=Q9Y2N7-5; Sequence=VSP_024519;
CC       Name=6; Synonyms=HIF-3alpha6 {ECO:0000303|PubMed:12538644};
CC         IsoId=Q9Y2N7-6; Sequence=VSP_024518, VSP_024521;
CC       Name=7;
CC         IsoId=Q9Y2N7-7; Sequence=VSP_043429;
CC   -!- TISSUE SPECIFICITY: Expressed in vascular cells (at protein level)
CC       (PubMed:21069422). Expressed in kidney (PubMed:11573933,
CC       PubMed:19694616). Expressed in lung epithelial cells (PubMed:16775626).
CC       Expressed in endothelial cells (venous and arterial cells from
CC       umbilical cord and aortic endothelial cells) and in vascular smooth
CC       muscle cells (aorta) (PubMed:21069422). Strongly expressed in the
CC       heart, placenta, and skeletal muscle, whereas a weak expression profile
CC       was found in the lung, liver, and kidney (PubMed:12538644). Expressed
CC       weakly in cell renal cell carcinoma (CC-RCC) compared to normal renal
CC       cells (PubMed:16126907). Expression is down-regulated in numerous
CC       kidney tumor cells compared to non tumor kidney tissues
CC       (PubMed:16126907). Isoform 2 is expressed in heart, placenta, lung,
CC       liver, skeletal muscle and pancreas and in numerous cancer cell lines
CC       (PubMed:20416395). Isoform 3 and isoform 4 are weakly expressed in
CC       heart, placenta, lung, liver, skeletal muscle and pancreas
CC       (PubMed:20416395). Isoform 4 is expressed in fetal tissues, such as
CC       heart, brain, thymus, lung, liver, skeletal kidney and spleen
CC       (PubMed:20416395). Isoform 3 is weakly expressed in fetal tissues, such
CC       as liver and kidney (PubMed:20416395). {ECO:0000269|PubMed:11573933,
CC       ECO:0000269|PubMed:12538644, ECO:0000269|PubMed:16126907,
CC       ECO:0000269|PubMed:16775626, ECO:0000269|PubMed:19694616,
CC       ECO:0000269|PubMed:20416395, ECO:0000269|PubMed:21069422}.
CC   -!- INDUCTION: Up-regulated by hypoxia (at protein level)
CC       (PubMed:16775626). Induced by hypoxia (PubMed:16775626). Isoform 2,
CC       isoform 3, isoform 4 and isoform 5 are up-regulated by hypoxia in a
CC       HIF1A- and EPAS1/HIF2A-dependent manner (PubMed:19694616,
CC       PubMed:20416395, PubMed:21069422). Isoform 4 is down-regulated by
CC       hypoxia and up-regulated upon restoring normoxia in embryonic kidney
CC       cells (PubMed:16126907). {ECO:0000269|PubMed:16126907,
CC       ECO:0000269|PubMed:16775626, ECO:0000269|PubMed:19694616,
CC       ECO:0000269|PubMed:20416395, ECO:0000269|PubMed:21069422}.
CC   -!- PTM: In normoxia, hydroxylated on Pro-492 in the oxygen-dependent
CC       degradation domain (ODD) by prolyl hydroxylase(s) (PHD). The
CC       hydroxylated proline promotes interaction with VHL, initiating rapid
CC       ubiquitination and subsequent proteasomal degradation.
CC       {ECO:0000269|PubMed:12538644}.
CC   -!- PTM: Ubiquitinated; ubiquitination occurs in a VHL- and oxygen-
CC       dependent pathway and subsequently targeted for proteasomal
CC       degradation. {ECO:0000269|PubMed:12538644}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Incomplete sequence. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Incomplete sequence. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL69947.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAB13865.1; Type=Miscellaneous discrepancy; Note=Aberrant splicing site.; Evidence={ECO:0000305};
CC       Sequence=BAB14824.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305};
CC       Sequence=BAB55324.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAD93355.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAG07185.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Hypoxia inducible factor entry;
CC       URL="https://en.wikipedia.org/wiki/Hypoxia_inducible_factor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB054067; BAB69689.1; -; mRNA.
DR   EMBL; AF463492; AAL69947.1; ALT_SEQ; mRNA.
DR   EMBL; AB118749; BAD93355.1; ALT_SEQ; mRNA.
DR   EMBL; AB295039; BAG07185.1; ALT_SEQ; mRNA.
DR   EMBL; AK021653; BAB13865.1; ALT_SEQ; mRNA.
DR   EMBL; AK024095; BAB14824.1; ALT_SEQ; mRNA.
DR   EMBL; AK027725; BAB55324.1; ALT_SEQ; mRNA.
DR   EMBL; AK297828; BAG60164.1; -; mRNA.
DR   EMBL; AC007193; AAD22668.1; -; Genomic_DNA.
DR   EMBL; CH471126; EAW57410.1; -; Genomic_DNA.
DR   EMBL; BC026308; AAH26308.1; -; mRNA.
DR   EMBL; BC080551; AAH80551.1; -; mRNA.
DR   CCDS; CCDS12681.2; -. [Q9Y2N7-1]
DR   CCDS; CCDS12682.1; -. [Q9Y2N7-2]
DR   CCDS; CCDS42580.2; -. [Q9Y2N7-7]
DR   PIR; JC7771; JC7771.
DR   RefSeq; NP_071907.4; NM_022462.4. [Q9Y2N7-7]
DR   RefSeq; NP_690007.1; NM_152794.3. [Q9Y2N7-2]
DR   RefSeq; NP_690008.2; NM_152795.3. [Q9Y2N7-1]
DR   PDB; 4WN5; X-ray; 1.15 A; A/B=237-347.
DR   PDBsum; 4WN5; -.
DR   AlphaFoldDB; Q9Y2N7; -.
DR   SMR; Q9Y2N7; -.
DR   BioGRID; 122143; 5.
DR   ELM; Q9Y2N7; -.
DR   STRING; 9606.ENSP00000366898; -.
DR   iPTMnet; Q9Y2N7; -.
DR   PhosphoSitePlus; Q9Y2N7; -.
DR   BioMuta; HIF3A; -.
DR   DMDM; 145558932; -.
DR   MassIVE; Q9Y2N7; -.
DR   PaxDb; Q9Y2N7; -.
DR   PeptideAtlas; Q9Y2N7; -.
DR   ProteomicsDB; 85845; -. [Q9Y2N7-1]
DR   ProteomicsDB; 85846; -. [Q9Y2N7-2]
DR   ProteomicsDB; 85847; -. [Q9Y2N7-3]
DR   ProteomicsDB; 85849; -. [Q9Y2N7-5]
DR   ProteomicsDB; 85851; -. [Q9Y2N7-7]
DR   Antibodypedia; 18071; 418 antibodies from 31 providers.
DR   DNASU; 64344; -.
DR   Ensembl; ENST00000244303.10; ENSP00000244303.6; ENSG00000124440.16. [Q9Y2N7-7]
DR   Ensembl; ENST00000300862.7; ENSP00000300862.3; ENSG00000124440.16. [Q9Y2N7-2]
DR   Ensembl; ENST00000377670.9; ENSP00000366898.3; ENSG00000124440.16. [Q9Y2N7-1]
DR   GeneID; 64344; -.
DR   KEGG; hsa:64344; -.
DR   MANE-Select; ENST00000377670.9; ENSP00000366898.3; NM_152795.4; NP_690008.2.
DR   UCSC; uc002peh.3; human. [Q9Y2N7-1]
DR   AGR; HGNC:15825; -.
DR   CTD; 64344; -.
DR   DisGeNET; 64344; -.
DR   GeneCards; HIF3A; -.
DR   HGNC; HGNC:15825; HIF3A.
DR   HPA; ENSG00000124440; Low tissue specificity.
DR   MIM; 609976; gene.
DR   neXtProt; NX_Q9Y2N7; -.
DR   OpenTargets; ENSG00000124440; -.
DR   PharmGKB; PA29285; -.
DR   VEuPathDB; HostDB:ENSG00000124440; -.
DR   eggNOG; KOG3558; Eukaryota.
DR   GeneTree; ENSGT00940000161745; -.
DR   HOGENOM; CLU_010044_5_0_1; -.
DR   InParanoid; Q9Y2N7; -.
DR   OMA; AEPRSHF; -.
DR   OrthoDB; 5396877at2759; -.
DR   PhylomeDB; Q9Y2N7; -.
DR   TreeFam; TF317772; -.
DR   PathwayCommons; Q9Y2N7; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor. [Q9Y2N7-1]
DR   Reactome; R-HSA-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SignaLink; Q9Y2N7; -.
DR   SIGNOR; Q9Y2N7; -.
DR   BioGRID-ORCS; 64344; 19 hits in 1154 CRISPR screens.
DR   ChiTaRS; HIF3A; human.
DR   GenomeRNAi; 64344; -.
DR   Pharos; Q9Y2N7; Tbio.
DR   PRO; PR:Q9Y2N7; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q9Y2N7; protein.
DR   Bgee; ENSG00000124440; Expressed in mucosa of stomach and 149 other tissues.
DR   ExpressionAtlas; Q9Y2N7; baseline and differential.
DR   Genevisible; Q9Y2N7; HS.
DR   GO; GO:0000785; C:chromatin; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:GO_Central.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   CDD; cd19729; bHLH-PAS_HIF3a_PASD7; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1.
DR   Gene3D; 3.30.450.20; PAS domain; 2.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR021537; HIF_alpha-like.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR013655; PAS_fold_3.
DR   PANTHER; PTHR23043; HYPOXIA-INDUCIBLE FACTOR 1 ALPHA; 1.
DR   PANTHER; PTHR23043:SF18; HYPOXIA-INDUCIBLE FACTOR 3-ALPHA; 1.
DR   Pfam; PF11413; HIF-1; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1.
DR   SUPFAM; SSF55785; PYP-like sensor domain (PAS domain); 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Apoptosis; Cytoplasm;
KW   Developmental protein; Hydroxylation; Isopeptide bond; Mitochondrion;
KW   Nucleus; Reference proteome; Repeat; Repressor; Stress response;
KW   Transcription; Transcription regulation; Tumor suppressor; Ubl conjugation.
FT   CHAIN           1..669
FT                   /note="Hypoxia-inducible factor 3-alpha"
FT                   /id="PRO_0000284414"
FT   DOMAIN          14..67
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          82..154
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          227..297
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   REGION          1..27
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          77..100
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:Q0VBL6"
FT   REGION          230..274
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250|UniProtKB:Q0VBL6"
FT   REGION          354..389
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          430..451
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          452..581
FT                   /note="ODD"
FT   REGION          454..506
FT                   /note="NTAD"
FT   REGION          523..600
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          619..669
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           414..418
FT                   /note="LRRLL"
FT   MOTIF           490..497
FT                   /note="LAPYISMD"
FT   COMPBIAS        10..27
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        354..378
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        573..588
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        646..669
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         492
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:12538644"
FT   CROSSLNK        467
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:12538644"
FT   CROSSLNK        570
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:12538644"
FT   VAR_SEQ         1..120
FT                   /note="MALGLQRARSTTELRKEKSRDAARSRRSQETEVLYQLAHTLPFARGVSAHLD
FT                   KASIMRLTISYLRMHRLCAAGEWNQVGAGGEPLDACYLKALEGFVMVLTAEGDMAYLSE
FT                   NVSKHLGLS -> MRPAAGAARRPRCCTSWLTRCPSPAASAPTWTRPLSCASPSATCAC
FT                   TASAP (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043429"
FT   VAR_SEQ         1..86
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_024518"
FT   VAR_SEQ         1..56
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_024519"
FT   VAR_SEQ         1..8
FT                   /note="MALGLQRA -> MDWQDH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11573933"
FT                   /id="VSP_024520"
FT   VAR_SEQ         87..137
FT                   /note="ACYLKALEGFVMVLTAEGDMAYLSENVSKHLGLSQLELIGHSIFDFIHPCD
FT                   -> MRPAAGAARRPRCCTSWLTRCPSPAASAPTWTRPLSCASPSATCACTASAP (in
FT                   isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_024521"
FT   VAR_SEQ         293..363
FT                   /note="LLSKGQAVTGQYRFLARSGGYLWTQTQATVVSGGRGPQSESIVCVHFLISQV
FT                   EETGVVLSLEQTEQHSRRP -> CMYPISPGAKPAATWPPADTRTPQLPIPQDALPPHL
FT                   NTSSLLPKPQGTVSFLAPSYPVPRSFSPHLPPWWP (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16126907"
FT                   /id="VSP_024523"
FT   VAR_SEQ         364..669
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16126907"
FT                   /id="VSP_024525"
FT   VAR_SEQ         611..669
FT                   /note="SFLLTGGPAPGSLQDPSTPLLNLNEPLGLGPSLLSPYSDEDTTQPGGPFQPR
FT                   AGSAQAD -> VCWGINGILWPSLPSWLKPTVL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_024526"
FT   VARIANT         343
FT                   /note="Q -> R (in dbSNP:rs3764609)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_031731"
FT   VARIANT         463
FT                   /note="F -> L (in dbSNP:rs7253301)"
FT                   /id="VAR_031732"
FT   MUTAGEN         467
FT                   /note="K->R: No loss of ubiquitination. Reduced
FT                   ubiquitination; when associated with R-570."
FT                   /evidence="ECO:0000269|PubMed:12538644"
FT   MUTAGEN         492
FT                   /note="P->A: Reduced hydroxylation activity. Reduced
FT                   ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:12538644"
FT   MUTAGEN         570
FT                   /note="K->R: No loss of ubiquitination. Reduced
FT                   ubiquitination; when associated with R-467."
FT                   /evidence="ECO:0000269|PubMed:12538644"
FT   CONFLICT        202
FT                   /note="A -> V (in Ref. 5; BAB55324)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        497
FT                   /note="D -> G (in Ref. 5; BAB55324)"
FT                   /evidence="ECO:0000305"
FT   STRAND          241..245
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   STRAND          250..254
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   HELIX           258..262
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   HELIX           266..269
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   TURN            280..282
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   HELIX           283..296
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   STRAND          297..300
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   STRAND          304..307
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   STRAND          313..323
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   HELIX           329..331
FT                   /evidence="ECO:0007829|PDB:4WN5"
FT   STRAND          333..342
FT                   /evidence="ECO:0007829|PDB:4WN5"
SQ   SEQUENCE   669 AA;  72433 MW;  81C4C84517000DE2 CRC64;
     MALGLQRARS TTELRKEKSR DAARSRRSQE TEVLYQLAHT LPFARGVSAH LDKASIMRLT
     ISYLRMHRLC AAGEWNQVGA GGEPLDACYL KALEGFVMVL TAEGDMAYLS ENVSKHLGLS
     QLELIGHSIF DFIHPCDQEE LQDALTPQQT LSRRKVEAPT ERCFSLRMKS TLTSRGRTLN
     LKAATWKVLN CSGHMRAYKP PAQTSPAGSP DSEPPLQCLV LICEAIPHPG SLEPPLGRGA
     FLSRHSLDMK FTYCDDRIAE VAGYSPDDLI GCSAYEYIHA LDSDAVSKSI HTLLSKGQAV
     TGQYRFLARS GGYLWTQTQA TVVSGGRGPQ SESIVCVHFL ISQVEETGVV LSLEQTEQHS
     RRPIQRGAPS QKDTPNPGDS LDTPGPRILA FLHPPSLSEA ALAADPRRFC SPDLRRLLGP
     ILDGASVAAT PSTPLATRHP QSPLSADLPD ELPVGTENVH RLFTSGKDTE AVETDLDIAQ
     DADALDLEML APYISMDDDF QLNASEQLPR AYHRPLGAVP RPRARSFHGL SPPALEPSLL
     PRWGSDPRLS CSSPSRGDPS ASSPMAGARK RTLAQSSEDE DEGVELLGVR PPKRSPSPEH
     ENFLLFPLSL SFLLTGGPAP GSLQDPSTPL LNLNEPLGLG PSLLSPYSDE DTTQPGGPFQ
     PRAGSAQAD
//
